Page 6 - Nsclc News Today

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.

The FDA and EMA have accepted applications seeking the approval of neoadjuvant nivolumab/chemotherapy followed by surgery and adjuvant nivolumab in NSCLC.

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

Inhaled chronic obstructive pulmonary disease (COPD) medications prescribed before surgery in patients with early-stage non–small cell lung cancer (NSCLC) were associated with both short- and long-term outcomes.

Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.

The FDA granted priority review to a sBLA seeking the approval of alectinib as adjuvant treatment after surgery for early-stage ALK-positive NSCLC.

Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.

A new cohort study shows that some immune-related adverse events are linked to longer survival in patients with NSCLC treated with immunotherapy.

Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).